Recap: Atea Pharmaceuticals Q4 Earnings
Recap: Atea Pharmaceuticals Q4 Earnings
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
Atea Pharmaceuticals beat estimated earnings by 6.0%, reporting an EPS of $-0.47 versus an estimate of $-0.5.
Revenue was down $0 from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.08 which was followed by a 9.0% drop in the share price the next day.
To track all earnings releases for Atea Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:05 PM.
Atea Pharmicals(納斯達克股票代碼:AVIR)於2024年2月28日星期三下午4點05分公佈了其第四季度業績。
Here's what investors need to know about the announcement.
以下是投資者需要了解的有關該公告的信息。
Earnings
收益
Atea Pharmaceuticals beat estimated earnings by 6.0%, reporting an EPS of $-0.47 versus an estimate of $-0.5.
Atea Pharmicals的收益比預期高出6.0%,每股收益爲-0.47美元,而預期爲-0.5美元。
Revenue was down $0 from the same period last year.
收入比去年同期下降了0美元。
Past Earnings Performance
過去的收益表現
Last quarter the company beat on EPS by $0.08 which was followed by a 9.0% drop in the share price the next day.
上個季度,該公司的每股收益高出0.08美元,隨後第二天股價下跌了9.0%。
To track all earnings releases for Atea Pharmaceuticals visit their earnings calendar here.
要追蹤Atea Pharmaceuticals的所有業績,請在此處訪問其業績日曆。
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由Benzinga的自動內容引擎生成,並由編輯審閱。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧